Lipid mediators in diabetic nephropathy

• Published in: Fibrogenesis & tissue repair Vol. 7; no. 1; p. 12
• Main Authors: Srivastava, Swayam Prakash, Shi, Sen, Koya, Daisuke, Kanasaki, Keizo
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 03.09.2014; BioMed Central
• Subjects: Analysis; Cholesterol; Development and progression; Diabetic nephropathies; Drug therapy; Fatty acids; Fish oils; Health aspects; Kinases; Low density lipoprotein; Physiological aspects; Protein kinases; Review; Studies; Type 2 diabetes; Antidyslipidaemic drugs and microRNAs (miRs); Protein kinase Cs (PKCs); Diabetic nephropathy (DN); Diacylglycerol (DAG); Glyceroshingolpids
• ISSN: 1755-1536; 1755-1536
• DOI: 10.1186/1755-1536-7-12

The implications of lipid lowering drugs in the treatment of diabetic nephropathy have been considered. At the same time, the clinical efficacy of lipid lowering drugs has resulted in improvement in the cardiovascular functions of chronic kidney disease (CKD) patients with or without diabetes, but no remarkable improvement has been observed in the kidney outcome. Earlier lipid mediators have been shown to cause accumulative effects in diabetic nephropathy (DN). Here, we attempt to analyze the involvement of lipid mediators in DN. The hyperglycemia-induced overproduction of diacyglycerol (DAG) is one of the causes for the activation of protein kinase C (PKCs), which is responsible for the activation of pathways, including the production of VEGF, TGFβ1, PAI-1, NADPH oxidases, and NFҟB signaling, accelerating the development of DN. Additionally, current studies on the role of ceramide are one of the major fields of study in DN. Researchers have reported excessive ceramide formation in the pathobiological conditions of DN. There is less report on the effect of lipid lowering drugs on the reduction of PKC activation and ceramide synthesis. Regulating PKC activation and ceramide biosynthesis could be a protective measure in the therapeutic potential of DN. Lipid lowering drugs also upregulate anti-fibrotic microRNAs, which could hint at the effects of lipid lowering drugs in DN.